Overview Checkpoint Therapeutics
SEC Filings and Financials. SEC Filings and Financials. Checkpoint Therapeutics Initiates Phase 12 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 A Novel Third Generation EGFR Inhibitor. Checkpoint Therapeutics, Inc. New York, NY 10014. SP Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the ent.
OVERVIEW
The site ir.checkpointtx.com currently has an average traffic ranking of zero (the lower the higher page views). We have analyzed seven pages within the website ir.checkpointtx.com and found seventy-five websites interfacing with ir.checkpointtx.com.
Pages Parsed
7Links to this site
75IR.CHECKPOINTTX.COM TRAFFIC
The site ir.checkpointtx.com has seen a fluctuation levels of traffic throughout the the year.
Date Range
1 week
1 month
3 months
This Year
Last Year
All time
Date Range
All time
This Year
Last Year
Date Range
All time
This Year
Last Year
Last Month
LINKS TO WEBSITE
Checkpoint Therapeutics A Fortress Biotech Company
A Fortress Biotech Company, is an innovative, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, targeted non-chemotherapy, and immune-enhanced combination treatments for patients with solid tumor cancers. New York, NY 10014.
WHAT DOES IR.CHECKPOINTTX.COM LOOK LIKE?
IR.CHECKPOINTTX.COM SERVER
We identified that a lone page on ir.checkpointtx.com took one thousand eight hundred and twenty-eight milliseconds to come up. We could not discover a SSL certificate, so our web crawlers consider ir.checkpointtx.com not secure.
Load time
1.828 sec
SSL
NOT SECURE
IP
216.197.69.202
BROWSER IMAGE
SERVER SOFTWARE
We discovered that this domain is employing the Microsoft-IIS/8.5 server.HTML TITLE
Overview Checkpoint TherapeuticsDESCRIPTION
SEC Filings and Financials. SEC Filings and Financials. Checkpoint Therapeutics Initiates Phase 12 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 A Novel Third Generation EGFR Inhibitor. Checkpoint Therapeutics, Inc. New York, NY 10014. SP Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the ent.PARSED CONTENT
The site ir.checkpointtx.com has the following on the web page, "Checkpoint Therapeutics Initiates Phase 12 Study of CK-101 A Novel Third-Generation EGFR Inhibitor." I noticed that the webpage also said " Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference." They also stated " Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 A Novel Third Generation EGFR Inhibitor. New York, NY 10014. TERMS AND CONDITIONS OF USE. These Terms of Use are the ent."ANALYZE MORE WEB SITES
locuos blog - nabil - Skyrock.com
1603;يف تتم صناعة الغباء.
Marty-Cullen meme - DeviantArt
Forgot Password or Username? Deviant for 7 Years.
ni-xa-mers blog - Fanny J. - Skyrock.com
Je vois pa trop en koi me sky ser dnc ji rentre pa tro souven! Alors que shui plus sur FACEBOOK. Shut Up and Let me Go The Ting Tings. JREPONDRAIS TOUJOUR O COMS BIENSUR.
Slashydraws Jade - DeviantArt
Forgot Password or Username? I got that. Deviant since Apr 5, 2016.